Rituximab 100mg/10ml Intravenous Infusion from Japan
Rituximab is a monoclonal antibody antineoplastic used for non-Hodgkin lymphoma and rheumatoid arthritis, provided in 100mg/10ml single-use vials for measured IV administration. It qualifies under HTS 3004.90.92.16 as an immunosuppressive biologic in dosed form.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Provide BLA (Biologics License Application) details and lot release certificates from FDA
• Use validated shipping containers for biologics to maintain 2-8°C chain of custody